Triple Combination Therapy for Global Cardiovascular Risk: Atorvastatin, Perindopril, and Amlodipine

  title={Triple Combination Therapy for Global Cardiovascular Risk: Atorvastatin, Perindopril, and Amlodipine},
  author={Michel E. Bertrand and Charalambos Vlachopoulos and Jean-Jacques Mourad},
  journal={American Journal of Cardiovascular Drugs},
Statins, angiotensin-converting enzyme (ACE) inhibitors, and calcium channel blockers (CCBs) have markedly changed the clinical progression of patients with coronary artery disease (CAD). The goal of this paper is to review the rationale and evidence for combining these three drug classes in hypertensive patients with hypercholesterolemia or CAD. Data sources include a literature search for publications on the use of a statin combined with various antihypertensive drugs in patients with… Expand
Treatment with triple combination of atorvastatin, perindopril, and amlodipine in patients with stable coronary artery disease: A subgroup analysis from the PAPA-CAD study
  • C. Dézsi
  • Medicine
  • The Journal of international medical research
  • 2018
Subgroup analyses of the previously published Hungarian Perindopril plus Amlodipine in PAtients with Coronary Artery Disease (PAPA-CAD) non-interventional trial demonstrated that the addition of the metabolically beneficial, fixed combination of perIndopril’+ amlodipines to atorvastatin further improves the patient’s lipid profile. Expand
Practical solutions for hypertensive patients with dyslipidemia
A review of the literature indicates that triple therapy with an angiotensin converting enzyme inhibitor, a calcium channel blocker and a statin is associated with a significant reduction in major cardiovascular events. Expand
Treatment with Free Triple Combination Therapy of Atorvastatin, Perindopril, Amlodipine in Hypertensive Patients: A Real-World Population Study in Italy
Real-world analysis among patients with free combination therapy can be applied to estimate the eligible population for fixed combination, and to evaluate the appropriateness of their prescriptions. Expand
Adherence to Treatment, Safety, Tolerance, and Effectiveness of Perindopril/Amlodipine Fixed-Dose Combination in Greek Patients with Hypertension and Stable Coronary Artery Disease: A Pan-Hellenic Prospective Observational Study of Daily Clinical Practice
The perindopril/amlodipine FDC is characterized by high adherence and effectiveness, regardless of previous treatment, and was related to baseline BP levels. Expand
Facing the Challenge of Lowering Blood Pressure and Cholesterol in the Same Patient: Report of a Symposium at the European Society of Hypertension
Overall, early intervention in patients with hypertension with use of an effective, high-intensity cardiovascular risk reduction regimen and attention to medication adherence through reducing pill burden are likely to result in optimal outcomes. Expand
Effect of intensive multifactorial treatment on vascular progenitor cells in hypertensive patients
Long-term intensive treatment in hypertensive patients further improves cardiovascular risk and increases circulating EPCs, suggesting that these cells could be a therapeutic target. Expand
Stroke risk and outcomes in patients with chronic kidney disease or end-stage renal disease: Two nationwide studies
CKD and ESRD patient groups faced significantly higher risk of stroke and post-stroke mortality, and were significantly higher in both sexes and every age group. Expand
Simultaneous Determination of Telmisartan and Pitavastatin calcium in Intestinal Perfusate by HPLC: Application to Intestinal Absorption Interaction Study.
Results showed telmisartan and pitavastatin calcium were transported passively, and tel Misartanand pitavASTatin calcium could be absorbed well in all intestinal segments, and the intestinal absorption parameters revealed the absence of any intestinal absorption interaction when co-administered. Expand
Ocena skuteczności leczenia hipotensyjnego pacjentów z nadciśnieniem tętniczym i chorobą niedokrwienną serca lub ekwiwalentem wieńcowym
It was revealed that main factors affecting poor blood pressure control after six months of observation were: obesity, age > 65 years, LDL cholesterol level > 130 mg/dL, and diabetes, which was more frequent in patients with diabetes mellitus. Expand
The Crossroads of Precision Medicine and Therapeutic Decision-Making: Use of an Analytical Computational Platform to Predict Response to Cancer Treatments
It is demonstrated that an algorithm reflecting the degree to which patients were matched to the drugs administered correctly ranked the response to the regimens with a specificity of 77%. Expand


Optimizing the treatment of hypertension and stable coronary artery disease: clinical evidence for fixed-combination perindopril/amlodipine
Evidence for the fixed combination of the angiotensin-converting enzyme (ACE) inhibitor perindopril and the calcium channel blocker amlodipine indicates it as a credible option for the optimization of the management of hypertension and CAD. Expand
Atorvastatin calcium plus amlodipine for the treatment of hypertension
The use of the single-pill amlodipine and atorvastatin is an adequate option for the clinician to treat hypertensive patients with DYL or high CV risk burden, with proven efficacy, tolerability, cost-effectiveness, and the advantage of improving patient treatment compliance. Expand
Effect of statins and ACE inhibitors alone and in combination on clinical outcome in patients with coronary heart disease
The statin+ACEI combination reduces cardiovascular events more than a statin alone and considerably more than an ACEI alone. Expand
Combination therapy in the extended cardiovascular continuum: a focus on perindopril and amlodipine
A strategy using ACE inhibitors and CCBs, such as perindopril and amlodipine, to target multiple stages in both pathways of cardiovascular disease could effectively reduce cardiovascular risk and lower BP. Expand
Angiotensin-converting-enzyme inhibitors in stable vascular disease without left ventricular systolic dysfunction or heart failure: a combined analysis of three trials
Results showing these benefits in intermediate-risk patients complement existing evidence of similar benefit in higher- risk patients with LVSD or heart failure and should be considered in all patients with atherosclerosis. Expand
Hypertension management: rationale for triple therapy based on mechanisms of action.
This review discusses the triple-therapy combination of an angiotensin receptor blocker (ARB) or direct renin antagonist (DRI) with a calcium channel blocker (CCB) and a diuretic, with a focus on mechanisms of action. Expand
Angiotensin System Blockade Combined With Calcium Channel Blockers Is Superior to Other Combinations in Cardiovascular Protection With Similar Blood Pressure Reduction: A Meta‐Analysis in 20,451 Hypertensive Patients
A+C therapy is superior to other combinations of antihypertensive treatment as it shows a lower incidence of cardiovascular events and adverse events, while it has similar effects in lowering BP and preserving renal function. Expand
Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled tri
The amlodipine-based regimen prevented more major cardiovascular events and induced less diabetes than the atenolol- based regimen, and these effects might not be entirely explained by better control of blood pressure. Expand
Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study)
Among patients with stable coronary heart disease without apparent heart failure, perindopril can significantly improve outcome, and these benefits were consistent in all predefined subgroups and secondary endpoints. Expand
Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients.
Ramipril significantly reduces the rates of death, myocardial infarction, and stroke in a broad range of high-risk patients who are not known to have a low ejection fraction or heart failure. Expand